Novel pharmacological activity for R-ketorolac in ovarian cancer

Novel pharmacological activity for R-ketorolac in ovarian cancer

(HealthDay)—The R-enantiomer of ketorolac is enriched in peritoneal fluids and inhibits peritoneal cell GTPase activity with administration after ovarian cancer surgery, according to a study published online June 12 in Clinical Cancer Research.

Noting that Rac1 and Cdc42 regulate cancer-relevant functions necessary for tumor cell adhesion and migration, Yuna Guo, from the University of New Mexico School of Medicine in Albuquerque, and colleagues examined the effects of administration of racemic (R, S) ketorolac after ovarian cancer surgery. Patients had suspected advanced stage, ovarian, fallopian tube, or primary peritoneal cancer. The authors assessed the association between perioperative ketorolac and ovarian cancer-specific survival.

The researchers detected elevated expression and activity of Rac1 and Cdc42 in tissues from patients, confirming target relevance. The R-enantiomer of ketorolac was enriched in peritoneal fluids, and peritoneal cell GTPase activity was inhibited after ketorolac administration when R-ketorolac was at peak levels. Women given perioperative ketorolac had a lower risk of death (hazard ratio, 0.30) after adjustment for age, American Joint Committee on Cancer stage, completion of chemotherapy, and neo-adjuvant therapy.

"Ketorolac has a novel pharmacologic activity conferred by the R-enantiomer, and R-ketorolac achieves sufficient levels in the to inhibit Rac1 and Cdc42, potentially contributing to the observed survival benefit in women who received ," the authors write.


Explore further

Ketorolac doesn't reduce pain with IUD placement

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Clinical Cancer Research

Copyright © 2015 HealthDay. All rights reserved.

Citation: Novel pharmacological activity for R-ketorolac in ovarian cancer (2015, August 4) retrieved 21 November 2019 from https://medicalxpress.com/news/2015-08-pharmacological-r-ketorolac-ovarian-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
8 shares

Feedback to editors

User comments